Toulouse, FRANCE, Lakeland, UNITED STATES, September 26, 2023, 8:00 p.m. CEST – ABIONYX Pharma, (FR0012616852 – ABNX – PEA PME eligible), new generation biotechnology company dedicated to the discovery and development of innovative therapies based on the sole recombinant apolipoprotein apoA-1 in the world, today announces its financial results for the first half of 2023.
Details of the main changes in the consolidated accounts
The Group recorded a consolidated half-year turnover of €2,128 thousand, a decrease compared to June 30, 2022. As a reminder, IRIS Pharma is the only company in the Group to generate turnover as of June 30, 2023. Concerning the activity dedicated to the discovery and development of innovative therapies aimed at improving the lives of patients, ABIONYX Pharma did not generate any revenue over this half-year. Since the integration of IRIS Pharma, the Group has focused its efforts on preclinical studies of bio-HDL as part of clinical development in ophthalmology.
Research and development costs amounted to €759,000 as of June 30, 2023, compared to €704,000 as of June 30, 2022. Since the start of the year, the company has successfully produced two first batches for industrial bioproduction. in GMP (Good Manufacturing Practices) of CER-001 using an innovative and robust method.
To receive information from ABIONYX Pharma in real time, send a request to [email protected].